Clinical review report: Naltrexone hydrochloride and bupropion hydrochloride (Contrave) (Bausch Health, Canada Inc.) : indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia)
The objective of the review is to perform a systematic review of the beneficial and harmful effects of naltrexone hydrochloride 8 mg and bupropion hydrochloride 90 mg (Contrave) extended-release tablets, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight manag...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa, (ON)
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of the review is to perform a systematic review of the beneficial and harmful effects of naltrexone hydrochloride 8 mg and bupropion hydrochloride 90 mg (Contrave) extended-release tablets, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia) |
|---|---|
| Physical Description: | 1 PDF file (121 pages) illustration |